Claim Check

From the latest edition of each brief.

Biotech & Pharma Intelligence

Claim Check · No. 052 · · About 2 min read

Five readouts checked against their registry records today. Two report their registered primaries; both RAS readouts lead with secondary endpoints; one TB trial gives no numbers for its primary.

ReadoutWhat the registry or primary source saysWhat the headline saysVerdict
ERAS-0015 · Erasca AURORAS-1 · NCT06983743 (opens another website in a new tab)Registered as Phase 1. Primaries: dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events, pharmacokinetics; response rate secondary. N=600 (planned); recruiting; primary completion 05.2028.Confirmed response rate 44% (n=25) in pancreatic cancer at 32 mg; no dose-limiting toxicitiesPartial
Daraxonrasib + chemotherapy · Revolution Medicines RMC-GI-102 · NCT06445062 (opens another website in a new tab) (our match)Phase 1/2 platform. Primaries for Subprotocols A to F, including the chemotherapy combination: adverse events and dose-limiting toxicities; response, progression-free and overall survival secondary. N=1,130 (planned); recruiting; primary completion 09.30.2028.Response rate 60.7%, median progression-free survival 12.8 months (n=61)Partial
Xanamem · Actinogen XanaMIA · NCT06125951 (opens another website in a new tab)Phase 2/3. Primaries: CDR-SB change at 36 weeks; adverse events. N=247; active, not recruiting; primary completion 09.22.2026.Primary missed: 0.10 points vs placebo, p = 0.65Match
Barzolvolimab · Celldex Atopic dermatitis · NCT06727552 (opens another website in a new tab)Phase 2. Primary: percent change in itch score (PP-NRS) at week 16. N=131; active, not recruiting; primary completion 05.06.2026.Primary missed at both doses; program stoppedMatch
AlpE · BioVersys ENABLE · NCT06748937 (opens another website in a new tab)Phase 2. Primary: early bactericidal activity over 14 days. N=60 (planned). Still reads recruiting past its 03.2026 primary completion date.All regimens bactericidal; no values givenOpen

ClinicalTrials.gov records pulled 11.20.2026 Reg; company releases (11.19 and 11.20) Co. Revolution’s release names the study, RMC-GI-102, but gives no registry number, so its record is our match by drug and design. A verdict compares what was announced with what was registered; it says nothing about whether the drug works.

Open a row on its own (5)

AI & Technology Intelligence

Claim Check · No. 052 · · About 1 min read

For each headline we opened the primary document where we could. Two match, one is partial and three are open.

ClaimWhat the primary document saysWhat the headline saysVerdict
Anthropic’s raise Closing releaseGross IPO proceeds about $93.5B; placement about $26.0B CoAnthropic raises almost $120 billionMatch
Chip licenses Committee release3.4 million chips requested; more than 879,000 approved GovNearly 880,000 AI chips approved for ChinaMatch
Commerce rule in force Federal RegisterEffective on publication, 11.19, per a law firm summary; Federal Register page not opened PressRemote-access chip rule takes effectOpen
Correction Index dataS&P 500 11.62% below its 10.06 record close; Dow close not confirmed by us DataS&P 500 and Dow close in correctionPartial
AMD firmware No primaryNo agency document; Hunterbrook says it cannot show a violationShort seller ties AMD firmware to blacklisted firmOpen
Nvidia and Inception No filingNo announcement by either companyNvidia nears deal for InceptionOpen
Open a row on its own (6)